Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTAI NASDAQ:MGNX NASDAQ:PRVB NASDAQ:URGN NASDAQ:VNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$3.11-8.3%$3.33$1.17▼$13.36$54.27M0.27.40 million shs2.56 million shsMGNXMacroGenics$1.59-3.6%$1.63$0.99▼$5.10$104.29M1.63935,919 shs491,283 shsPRVBProvention Bio$24.98$24.58$3.18▼$25.00$2.37B2.472.28 million shs218,200 shsURGNUrogen Pharma$18.79-2.4%$18.19$3.42▼$21.71$890.59M1.11.08 million shs886,418 shsVNDAVanda Pharmaceuticals$4.51-2.0%$4.60$3.81▼$5.55$271.81M0.74404,217 shs367,875 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics-8.26%-17.94%-44.46%+99.36%-64.59%MGNXMacroGenics-3.64%-20.50%-4.22%+4.61%-56.08%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%URGNUrogen Pharma-2.39%-0.48%-6.56%+56.19%+36.06%VNDAVanda Pharmaceuticals-1.96%-2.17%+3.44%0.00%-8.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$3.11-8.3%$3.33$1.17▼$13.36$54.27M0.27.40 million shs2.56 million shsMGNXMacroGenics$1.59-3.6%$1.63$0.99▼$5.10$104.29M1.63935,919 shs491,283 shsPRVBProvention Bio$24.98$24.58$3.18▼$25.00$2.37B2.472.28 million shs218,200 shsURGNUrogen Pharma$18.79-2.4%$18.19$3.42▼$21.71$890.59M1.11.08 million shs886,418 shsVNDAVanda Pharmaceuticals$4.51-2.0%$4.60$3.81▼$5.55$271.81M0.74404,217 shs367,875 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics-8.26%-17.94%-44.46%+99.36%-64.59%MGNXMacroGenics-3.64%-20.50%-4.22%+4.61%-56.08%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%URGNUrogen Pharma-2.39%-0.48%-6.56%+56.19%+36.06%VNDAVanda Pharmaceuticals-1.96%-2.17%+3.44%0.00%-8.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTAIBioXcel Therapeutics 2.67Moderate Buy$39.751,178.14% UpsideMGNXMacroGenics 2.57Moderate Buy$3.60126.42% UpsidePRVBProvention Bio 0.00N/AN/AN/AURGNUrogen Pharma 3.00Buy$32.0070.30% UpsideVNDAVanda Pharmaceuticals 3.50Strong Buy$16.50265.85% UpsideCurrent Analyst Ratings BreakdownLatest VNDA, URGN, PRVB, MGNX, and BTAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025BTAIBioXcel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/26/2025BTAIBioXcel TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/21/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/18/2025URGNUrogen PharmaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.008/15/2025BTAIBioXcel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.008/15/2025MGNXMacroGenicsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $5.008/11/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.008/5/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/8/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.007/7/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/16/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTAIBioXcel Therapeutics$868K57.36N/AN/A($30.01) per share-0.10MGNXMacroGenics$149.96M0.67N/AN/A$1.85 per share0.86PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84URGNUrogen Pharma$90.40M9.62N/AN/A($0.21) per share-89.48VNDAVanda Pharmaceuticals$198.77M1.34N/AN/A$9.24 per share0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTAIBioXcel Therapeutics-$59.60M-$12.64N/AN/AN/A-5,869.82%N/A-134.45%11/13/2025 (Estimated)MGNXMacroGenics-$66.97M-$0.57N/AN/AN/A-21.99%-40.24%-14.62%11/4/2025 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/AURGNUrogen Pharma-$126.87M-$3.32N/AN/AN/A-164.44%-97,487.15%-59.38%11/5/2025 (Estimated)VNDAVanda Pharmaceuticals-$18.90M-$1.13N/AN/AN/A-32.90%-12.89%-10.47%11/5/2025 (Estimated)Latest VNDA, URGN, PRVB, MGNX, and BTAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MGNXMacroGenics-$0.59-$0.57+$0.02-$0.57$28.06 million$22.24 million8/12/2025Q2 2025BTAIBioXcel Therapeutics-$2.30-$2.45-$0.15-$2.45$0.21 million$0.12 million8/7/2025Q2 2025URGNUrogen Pharma-$0.82-$1.05-$0.23-$1.05$23.06 million$24.22 million7/31/2025Q2 2025VNDAVanda Pharmaceuticals-$0.34-$0.46-$0.12-$0.46$54.77 million$52.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTAIBioXcel TherapeuticsN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTAIBioXcel TherapeuticsN/A0.760.74MGNXMacroGenicsN/A5.265.02PRVBProvention Bio0.191.931.92URGNUrogen PharmaN/A4.143.99VNDAVanda PharmaceuticalsN/A3.253.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTAIBioXcel Therapeutics30.68%MGNXMacroGenics96.89%PRVBProvention Bio37.39%URGNUrogen Pharma91.29%VNDAVanda Pharmaceuticals88.14%Insider OwnershipCompanyInsider OwnershipBTAIBioXcel Therapeutics21.20%MGNXMacroGenics13.00%PRVBProvention Bio13.10%URGNUrogen Pharma4.70%VNDAVanda Pharmaceuticals10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTAIBioXcel Therapeutics9016.01 million12.62 millionOptionableMGNXMacroGenics43063.21 million54.99 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableURGNUrogen Pharma20046.26 million44.09 millionOptionableVNDAVanda Pharmaceuticals29059.09 million53.18 millionOptionableVNDA, URGN, PRVB, MGNX, and BTAI HeadlinesRecent News About These CompaniesWellington Management Group LLP Cuts Stock Holdings in Vanda Pharmaceuticals Inc. $VNDASeptember 2, 2025 | marketbeat.comNuveen LLC Acquires Shares of 440,561 Vanda Pharmaceuticals Inc. $VNDASeptember 1, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $2.18 Million Stake in Vanda Pharmaceuticals Inc. $VNDASeptember 1, 2025 | marketbeat.comVanda: Next Phase Of Fanapt Growth Might Be With Bysanti AdvancementAugust 29, 2025 | seekingalpha.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia ...August 29, 2025 | finanznachrichten.deVanda Pharmaceuticals Announces Participation at September 2025 Investor ConferencesAugust 28, 2025 | prnewswire.comVanda Pharmaceuticals gets FDA orphan drug status for VGT-1849BAugust 28, 2025 | seekingalpha.comVanda Pharmaceuticals stock rises after FDA orphan drug designationAugust 28, 2025 | za.investing.comVanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia VeraAugust 28, 2025 | prnewswire.comVanda Pharmaceuticals treatment of polycythemia vera granted orphan designationAugust 27, 2025 | msn.comVanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at HC WainwrightAugust 23, 2025 | marketbeat.comVanda seeks FDA Commissioner review of Hetlioz generic rulingAugust 22, 2025 | msn.comVanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®August 21, 2025 | prnewswire.comVanda wins appeals court fight over FDA jet lag rulingAugust 19, 2025 | thepharmaletter.comTVanda Pharmaceuticals Shares Climb After Court Reverses FDA DecisionAugust 18, 2025 | msn.comVanda Pharmaceuticals shares rise after court overturns FDA denialAugust 18, 2025 | za.investing.comVanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-MarkAugust 18, 2025 | msn.comIn a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag DisorderAugust 18, 2025 | prnewswire.comHC Wainwright Issues Pessimistic Outlook for VNDA EarningsAugust 16, 2025 | marketbeat.comHC Wainwright Has Bearish Forecast for VNDA Q4 EarningsAugust 15, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $4.27 Million Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)August 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVNDA, URGN, PRVB, MGNX, and BTAI Company DescriptionsBioXcel Therapeutics NASDAQ:BTAI$3.11 -0.28 (-8.26%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.15 +0.04 (+1.29%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.MacroGenics NASDAQ:MGNX$1.59 -0.06 (-3.64%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.31%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Provention Bio NASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Urogen Pharma NASDAQ:URGN$18.79 -0.46 (-2.39%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$18.80 +0.01 (+0.03%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Vanda Pharmaceuticals NASDAQ:VNDA$4.51 -0.09 (-1.96%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.53 +0.02 (+0.44%) As of 09/12/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
